Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q3 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $105.5 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.